IMMX

Healthcare Biotechnology

Immix Biopharma, Inc.

$10.13

+0.60 +6.31% today

Price History

Not enough data

Key Stats

Market Cap

839.81M

Avg Volume

1.71M

EPS

-$0.88

52W High

$15.10

52W Low

$2.00

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-11.95

P/B Ratio

3.17

EV/EBITDA

-11.90

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(34.2%)

Return on Assets

(20.5%)

Liquidity & Leverage

Current Ratio

25.13

Quick Ratio

24.95

Debt / Equity

0.00

Total Cash

232.11M

Total Debt

1.00M

About

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.